MedTrace Logo

Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder

NCT03537950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-03-05

No results posted yet for this study

Summary

This study investigates brain response to single acute dose of cannabidiol, cannabidivarin, and placebo in healthy men with and without autism spectrum disorder

Conditions

Interventions

DRUG

PLC

Single oral dose of PLC.

DRUG

CBD

Single oral dose of cannabidiol (CBD) - 600mg.

DRUG

CBDV

Single oral dose of cannabidivarin (CBDV) - 600mg.

Sponsors & Collaborators

Principal Investigators

  • Grainne McAlonan, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-22
Primary Completion
2017-02-16
Completion
2017-03-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03537950 on ClinicalTrials.gov